Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02086591 · OUTCOME

Overall Response Rate

A Phase II Study of Doxycycline in Relapsed NHL · Source last updated 2016-12-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Three months

What was measured

Overall response rate is defined as the percentage of patients with disease progression. Progression is defined as: * Appearance of a new lesion on fluorodeoxyglucose (FDG)-positron emission tomography or computerized tomography * ≥50% increase in sum of the product of the node dimensions (SPD) of more than one node or in greatest diameter of any previously identified node \>1 cm in its short axis from nadir. * To be considered progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must increase by 50% and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis. * At least a 50% increase in the longest diameter of any single previously identified node more than 1 cm in its short axis.

Groups in this outcome

Doxycycline

Doxycycline 200 mg twice daily Doxycycline

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Doxycycline7

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Doxycycline28Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        28
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    units
    Participants
description
Overall response rate is defined as the percentage of patients with disease progression. Progression is defined as: * Appearance of a new lesion on fluorodeoxyglucose (FDG)-positron emission tomography or computerized tomography * ≥50% increase in sum of the product of the node dimensions (SPD) of more than one node or in greatest diameter of any previously identified node \>1 cm in its short axis from nadir. * To be considered progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must increase by 50% and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis. * At least a 50% increase in the longest diameter of any single previously identified node more than 1 cm in its short axis.
groups
  1. description
    Doxycycline 200 mg twice daily Doxycycline
    id
    OG000
    title
    Doxycycline
param Type
NUMBER
reporting Status
POSTED
time Frame
Three months
title
Overall Response Rate
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice